INSM vs ONC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Insmed Incorporated exhibits a weak deterministic health profile with a Piotroski F-Score of 3/9, indicating significant fundamental instability. While the company shows explosive revenue growth of 152.6%, this is offset by extreme valuation metrics (Price/Sales of 55.10) and a consistent track record of missing earnings estimates (0/4 beats in the last year). The stark disconnect between the 'Strong Buy' analyst consensus and the bearish insider activity—including significant sales by the CEO and COO—suggests a high-risk speculative profile rather than a value-driven investment.
ONC exhibits strong operational health with a Piotroski F-Score of 7/9 and a robust balance sheet characterized by low debt (D/E 0.25) and high liquidity. However, there is a severe disconnect between the current market price ($319.94) and deterministic value metrics, with the Graham Number ($47.6) and Intrinsic Value ($17.92) suggesting massive overvaluation. While the company has successfully transitioned from deep historical losses to profitability and maintains strong revenue growth (32.8%), aggressive insider selling by the CEO and a bearish technical trend offset the 'Strong Buy' analyst consensus.
Compare Another Pair
Related Comparisons
INSM vs ONC: Head-to-Head Comparison
This page compares Insmed Incorporated (INSM) and BeOne Medicines AG (ONC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.